ZLAB vs ABBV vs MRK vs JAZZ vs BIIB

For growth investors, Zai Lab Limited (ZLAB) is the stronger pick with 15.

3% revenue growth year-over-year, versus 1. 2% for Merck & Co. , Inc. (MRK). Merck & Co. , Inc. (MRK) offers the better valuation at 15. 4x trailing P/E (21. 9x forward), making it the more compelling value choice. Analysts rate Zai Lab Limited (ZLAB) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Merck & Co.

, Inc. (MRK) is the cheapest at 15. 4x versus AbbVie Inc. at 85. 5x. On forward P/E, Jazz Pharmaceuticals plc is actually cheaper at 9. 4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +101. 3%, compared to -87. 5% for Zai Lab Limited (ZLAB). Over 10 years, the gap is even starker: ABBV returned +295. 5% versus ZLAB's -29. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 34β versus Zai Lab Limited's 1. 21β — meaning ZLAB is approximately 258% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Zai Lab Limited (ZLAB) carries a lower debt/equity ratio of 31% versus 126% for Jazz Pharmaceuticals plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Zai Lab Limited (ZLAB) is pulling ahead at 15.

3% versus 1. 2% for Merck & Co. , Inc. (MRK). On earnings-per-share growth, the picture is similar: Zai Lab Limited grew EPS 38. 5% year-over-year, compared to -167. 5% for Jazz Pharmaceuticals plc. Over a 3-year CAGR, ZLAB leads at 28. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Merck & Co.

, Inc. (MRK) is the more profitable company, earning 28. 1% net margin versus -38. 1% for Zai Lab Limited — meaning it keeps 28. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MRK leads at 36. 2% versus -49. 9% for ZLAB. At the gross margin level — before operating expenses — JAZZ leads at 88. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Jazz Pharmaceuticals plc (JAZZ) trades at 9.

4x forward P/E versus 21. 9x for Merck & Co. , Inc. — 12. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ZLAB: 77. 1% to $35. 00.

In this comparison, ABBV (3.

2% yield), MRK (2. 9% yield) pay a dividend. ZLAB, JAZZ, BIIB do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34), 3. 2% yield, +295. 5% 10Y return). Both have compounded well over 10 years (ABBV: +295. 5%, ZLAB: -29. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ZLAB is a small-cap high-growth stock; ABBV is a large-cap income-oriented stock; MRK is a large-cap deep-value stock; JAZZ is a mid-cap quality compounder stock; BIIB is a mid-cap quality compounder stock. ABBV, MRK pay a dividend while ZLAB, JAZZ, BIIB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.